Loading
A phase 3 trial of Ziftomenib, Venetoclax, Azacitidine, Daunorubicin and Cytarabine in acute myeloid leukaemia, run by Kura Oncology, Inc., now recruiting.
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML is a phase 3 interventional study registered as NCT07007312 by Kura Oncology, Inc., with 1300 participants planned, started 2025-09-26 and due to reach its primary completion in 2031-11. Interventions recorded: Ziftomenib, Placebo, Venetoclax, Azacitidine (AZA), Daunorubicin and Cytarabine (Ara-C).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Daunorubicin, BCL-2 inhibitors, Cytarabine, Azacitidine and the tag pipeline.
Shares BCL-2 inhibitors, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Venetoclax and the tag pipeline.
Shares BCL-2 inhibitors, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Venetoclax and the tag pipeline.
Shares BCL-2 inhibitors, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Venetoclax and the tag pipeline.
Shares BCL-2 inhibitors, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Venetoclax and the tag pipeline.
Shares BCL-2 inhibitors, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Venetoclax and the tag pipeline.
Shares BCL-2 inhibitors, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Venetoclax and the tag pipeline.
Shares BCL-2 inhibitors, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Venetoclax and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/